TY  - JOUR 
AU  - García Azorín, David
AU  - Martínez, Blanca
AU  - Gutiérrez, María
AU  - Ruiz Piñero, Marina
AU  - Echavarría, Ana
AU  - Sierra, Álvaro
AU  - Guerrero Peral, Angel Luis
PY  - 2022
SN  - 2072-6651
UR  - https://uvadoc.uva.es/handle/10324/60398
AB  - Onabotulinumtoxin A (onabotA) has shown efficacy in chronic migraine (CM), with good tolerability and a low rate of adverse effects, most of them not severe. The aim of this study is to evaluate tolerability and adverse effects of onabotA in clinical...
LA  - eng
PB  - MDPI
KW  - Botulinum toxin - Therapeutic use
KW  - Toxina botulínica
KW  - Neurology
KW  - Migraine
KW  - Migraña
KW  - Chronic pain
KW  - Dolor crónico
KW  - Pain medicine
KW  - Pain - Treatment
KW  - Dolor - Tratamiento
KW  - Médicaments - Effets secondaires
KW  - Medicamentos - Efectos secundarios
KW  - Toxicology
TI  - Real-world evaluation of the tolerability to onabotulinum toxin A: The RETO study
DO  - 10.3390/toxins14120850
ER  -